戻る Agenda
Welcome to Day 2 and Session 6: Keynote Address - Delivery of Oligonucleotide Therapeutics – Going Beyond the Liver
Session Chair(s)
Andrew Adams, PHD, MBA
Vice President, Genetic Medicine
Eli Lilly and Company, United States
Discussion of the challenges and opportunities of next generation delivery approaches for RNA and DNA based medicines. Approaches spanning direct conjugation of ligands, antibody/peptide conjugates, blood brain barrier shuttles and nanoparticles will be covered, as well as potential therapeutic applications.